Skip to content

TANDem-2: Closing the Gap to Interventions for TAND

TANDem-2: Closing the Gap to Interventions for TAND

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06879665
Acronym
TANDem-2
Enrollment
30
Registered
2025-03-17
Start date
2025-07-15
Completion date
2027-07-15
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Caregivers of Individuals With TSC, Tuberous Sclerosis Complex (TSC)

Keywords

Caregiver well-being, Psychological flexibility, Acceptance and Commitment Therapy (ACT), Tuberous sclerosis complex (TSC), TSC-Associated Neuropsychiatric Disorders (TAND)

Brief summary

The goal of this pilot study is to determine the feasibility, acceptability and impact of a brief behavioral intervention - the Well-Beans for Caregivers program, for adult caregivers of individuals with tuberous sclerosis complex (TSC) of any age. The main questions of the study are: 1. Can this innovative, ultra-brief caregiver well-being intervention be delivered feasibly to caregivers via an online modality? 2. How do the caregivers experience the program (acceptability)? 3. Does limited efficacy testing suggest the program has an impact on caregiver's well-being?

Detailed description

The investigators hypothesize that an innovative, ultra-brief caregiver wellbeing intervention developed for caregivers of children with developmental disabilities can be adapted as a universal caregiver wellbeing intervention in tuberous sclerosis complex (TSC), that it can be delivered feasibly in an online modality, and will result in changes in key caregiver wellbeing factors. To test these hypotheses, the researchers will adapt the 3-session 'Well-Beans for Caregivers' program through a participatory method with the TAND consortium (the TAND consortium is an international group of clinical and research professionals as well as family members living with individuals with TSC - TAND stands for TSC-Associated Neuropsychiatric Disorders - see tandconsortium.org). The input from the TAND Consortium will be augmented by members of TSCi (Tuberous Sclerosis International), the global network of TSC non-profit organizations. For step 2 (pilot intervention), two specialist facilitators and four trainee observers will deliver the 3-session program using ZoomPro, a secure online platform to two groups of 10-12 caregivers. Caregivers are those who provide long-term, day-to-day support and care, and this group includes parents, partners, relatives, or other family members (not paid professional caregivers). These sessions will not be recorded to ensure that participants can join the program without feeling concerned about being recorded. Data collection will use a quasi-experimental pre-post-test design. Eligible and consented participants will therefore complete baseline data as 'pre-test' and then 'post-test' data after the 3-week intervention. Following this, they will complete 3-month and 6-month data collection. Caregiver wellbeing measures will only include open access and freely available measures. The program as well as data collection will be conducted in English.

Interventions

BEHAVIORALWell-Beans for Caregivers Program

This is a brief behavioral intervention consisting of 3 weekly 2-hour sessions. The sessions are based on Acceptance and Commitment Therapy (ACT) and are designed to improve psychological flexibility in caregivers. This in turn is designed to help them connect with their difficult emotions and experiences in a flexible way, and improve emotional well-being.

Sponsors

University of Cape Town
CollaboratorOTHER
United States Department of Defense
CollaboratorFED
Vrije Universiteit Brussel
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult caregiver of an individual with Tuberous Sclerosis Complex (TSC) of any age

Exclusion criteria

* Not an adult caregiver of an individual with TSC

Design outcomes

Primary

MeasureTime frameDescription
Feasibility Feedback Forms for caregivers, facilitators and observersAt the end of cycle 1, cycle 2 and cycle 3 (each cycle is 7 days)Caregivers, facilitators and observers will complete bespoke Feasibility Feedback Forms to assess whether the intervention could be implemented as designed.
Attendance rates to assess feasibilityAt the end of cycle 1, cycle 2 and cycle 3 (each cycle is 7 days)Attendance rates at each of the three weekly intervention sessions will be tracked as a measure of feasibility of the intervention program.
Acceptability Feedback Forms for caregivers, facilitators and observersAt the end of cycle 1, cycle 2 and cycle 3 (each cycle is 7 days)Caregivers, facilitators and observers will complete bespoke Acceptability Feedback Forms to assess their experience and acceptability of the program.

Secondary

MeasureTime frameDescription
Change in general wellbeing scores on the World Health Organization Wellbeing Index (WHO-5)Change from baseline to immediately post-, and 3 and 6-month post treatmentChanges in general wellbeing will be assessed via changes in scores on the WHO-5 Wellbeing Index (WHO-5). This is a 5-item scale with a minimum score of 0 and a maximum score of 25. Higher scores indicate higher levels of well-being.
Change in psychological flexibility on the Psy-Flex measureChange from baseline to immediately post-treatment, and at 3 and 6 months post-treatmentChanges in scores on the Psy-Flex (Gloster, 2021) will be used to assess changes in caregiver psychological flexibility from before to after treatment. The Psy-Flex consists of 6 items with a minimum score of 6 and a maximum score of 30. Higher scores indicate better psychological flexibility (better outcome).
Change in resilience as measured on the Brief Resilience ScaleChange from baseline to immediately post-, and 3 and 6-month post treatmentChanges in resilience will be assessed via changes in scores on the Brief Resilience Scale (BRS). The BRS is a 6-item scale with a minimum score of 6 and a maximum score of 30. Higher scores indicate higher levels of resilience.
Change in depression on the Patient Health Questionnaire-9 (PHQ-9)Change from baseline to immediately post-, and 3 and 6-month post treatmentChanges in participant levels of depression will be measured via changes in scores on the Patient Health Questionnaire (PHQ-9) from before to after the intervention and at two follow-up intervals. The PHQ consists of 9 items with a minimum score of 0 and a maximum score of 27. Higher scores indicate higher levels of depression.
Change in anxiety on the Generalized Anxiety Disorder-7 Scale (GAD-7)Change from baseline to immediately post-, and 3 and 6-month post treatmentChanges in anxiety will be assessed via changes in scores on the Generalized Anxiety Disorder-7 Scale (GAD-7). This is a 7-item scale with a minimum score of 0 and a maximum score of 21. Higher scores indicate higher levels of anxiety.

Countries

Australia, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026